Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 109 P95 | DOI: 10.1530/endoabs.109.P95

SFEBES2025 Poster Presentations Endocrine Cancer and Late Effects (9 abstracts)

The use of empagliflozin for paraneoplastic siadh: observations from a real-world cohort treated at a tertiary oncology centre

Amit Singh 1 , Maria Michaelidou 1 , Laura Cove-Smith 1 , Shaishav Dhage 1 , Tim Cooksley 1 , Jan Hoong Ho 1 & Safwaan Adam 1,2


1The Christie Hospital, Manchester, United Kingdom; 2The University of Manchester, Manchester, United Kingdom


Paraneoplastic syndrome of inappropriate antidiuretic hormone (pSIADH) is common and increases cancer-related morbidity. In addition to anti-cancer therapy, the usual management of pSIADH includes fluid restriction and pharmacotherapy with demeclocycline or vasopressin receptor antagonists. These measures show variable effectiveness, require intense monitoring, and can cause serious toxicity. Previous studies have demonstrated the efficacy of the sodium-glucose cotransporter-2 inhibitor empagliflozin in managing patients with SIADH. We report our experience of empagliflozin use specifically in patients with pSIADH due to metastatic cancer at The Christie Hospital, a tertiary oncology centre in North-West England. Fifteen patients with pSIADH attending our acute oncology unit were commenced on empaglifozin between September 2023 and August 2024. Baseline characteristics, indication, and response to treatment are described in Table 1. One patient reported nocturia as a side-effect, however there were no episodes of ketoacidosis or urinary tract infections recorded in our cohort. Despite the small cohort, our findings indicate a potential role for empagliflozin in managing pSIADH. Further research is needed to corroborate our observations.

Table 1. Performance of the best ML models
Variable Number/Finding Comments
Sex
Male0
Female7
Primary Malignancy
Small-cell lung10
Non-small-cell lung1
Prostate2
Vulval1
Lymphoma1
Baseline Sodium (mmol/l)
Median (min-max range)119 (116-126)
Indication for treatment
Suboptimal/poor response to other measures
Tolvaptan1
Demeclocycline3
Fluid Restriction alone3
Hyperglycaemia +SIADH3
Side-effects1
Cautions/contra-indications with other agents
Dose7
10 mg7
25 mg8
Sustained improvement in sodium to >125 mmol/L
1 week13/15
1 month8/1113/15 died due to progressive cancer.
3 months7/91 stopped empagliflozin (after 6-months) due to resolution of pSIADH
6 months4/5
9 mont7/hs2/2
12 months1/1
Median Sodium in mmol/L (min-max range)
1 week127 (116-138)
1 month131 (118-139)
3 months130 (114-141)
6 months133 (122-142)

Volume 109

Society for Endocrinology BES 2025

Harrogate, UK
10 Mar 2025 - 12 Mar 2025

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches